CymaBay Therapeutics scraps liver disease studies; shares plunge

CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage studies testing its experimental drug in patients with non-alcoholic steatohepatitis (NASH) and another liver disease after it observed "atypical" findings in one trial, sending shares down 76% in premarket trading.

from Reuters: Health News https://ift.tt/37CLkyM
via IFTTT